Compare Citius Pharmaceuticals Inc (CTXR) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Toronto-Dominion Bank — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Toronto-Dominion Bank trades at $123.8 (market cap $198.63B). The key difference: Toronto-Dominion Bank is far larger — about 13567.6× Citius Pharmaceuticals Inc's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TD | |
|---|---|---|
Market Cap | $14.64M | $198.63B |
Sector | Health | Financials |
52-Week High | $1.82 | $122.88 |
52-Week Low | $0.53 | $72.55 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TD trades at $120.63, up 0.08% today, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 results pending. Revenue grew to $61.28 billion in 2025, and net income margin improved to 33.51%. Recent news highlights strong Q2 2026 earnings and a dividend increase.
The outlook is positive, supported by earnings momentum, a high analyst buy rating (52.94%), and operational efficiency gains from AI. Key risks include volatile cash flows, high debt levels, and economic sensitivity. The stock offers a solid dividend and growth potential, but investors should monitor credit performance and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
